TRDA

MKT CAP:$479M

Entrada Therapeutics, Inc.

Market Cap

$479M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$13.05+$3.00 (+29.85%)

Apr 22, 2026

Company Details

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, a...

CEO

Dipal Doshi

IPO Date

Oct 29, 2021

Website

www.entradatx.com

Key Metrics TTM

Revenue

$25M

-87.9% YoY

Net Income

-$144M

EPS (Diluted)

-$3.47

Free Cash Flow

-$130M

Revenue / Share

$0.61

Gross Margin

-54.4%

Operating Margin

-621.1%

Net Margin

-565.5%

FCF Margin

-509.6%

P/S

18.8x

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Feb 26, 2026

$25M-87.9%EPS -$3.47

Q4 2025

Feb 26, 2026

$1M-96.5%EPS -$0.95

Q3 2025

Nov 6, 2025

$2M-91.8%EPS -$1.06

Q2 2025

Aug 6, 2025

$2M-97.9%EPS -$1.04

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$22M
Q2 22	$0	$0	-$24M
Q3 22	$0	$0	-$26M
Q4 22	$0	$0	-$26M
Q1 23	$25M	$2M	-$6M
Q2 23	$18M	-$8M	-$16M
Q3 23	$44M	$22M	$14M
Q4 23	$42M	$42M	$5M
Q1 24	$59M	$59M	$21M
Q2 24	$95M	$95M	$53M
Q3 24	$20M	$20M	-$22M
Q4 24	$37M	$37M	-$6M
Q1 25	$21M	$21M	-$22M
Q2 25	$2M	$2M	-$47M
Q3 25	$2M	-$37M	-$47M
Q4 25	$1M	$413.0K	-$42M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	20.0x	—
Q2 23	11.2x	—
Q3 23	5.7x	—
Q4 23	4.1x	—
Q1 24	2.8x	19.6x
Q2 24	2.0x	4.6x
Q3 24	2.5x	9.9x
Q4 24	3.3x	10.8x
Q1 25	2.1x	14.9x
Q2 25	3.5x	—
Q3 25	3.9x	—
Q4 25	16.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$21M	-$22M
Q2 22	-$18M	-$19M
Q3 22	-$27M	-$28M
Q4 22	-$27M	-$28M
Q1 23	$203M	$202M
Q2 23	-$35M	-$37M
Q3 23	-$24M	-$26M
Q4 23	-$4M	-$5M
Q1 24	-$26M	-$26M
Q2 24	$40M	$39M
Q3 24	-$24M	-$25M
Q4 24	-$32M	-$32M
Q1 25	-$39M	-$40M
Q2 25	-$29M	-$30M
Q3 25	-$28M	-$28M
Q4 25	-$32M	-$32M

Capital Expenditures

Quarter	CapEx
Q1 22	$594.0K
Q2 22	$775.0K
Q3 22	$810.0K
Q4 22	$708.0K
Q1 23	$2M
Q2 23	$2M
Q3 23	$1M
Q4 23	$976.0K
Q1 24	$838.0K
Q2 24	$1M
Q3 24	$639.0K
Q4 24	$635.0K
Q1 25	$1M
Q2 25	$275.0K
Q3 25	$171.0K
Q4 25	$207.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+163.9%
Q2 22	—	+138.0%
Q3 22	—	+80.6%
Q4 22	—	+38.6%
Q1 23	—	+40.1%
Q2 23	—	+46.2%
Q3 23	—	+14.6%
Q4 23	—	+44.4%
Q1 24	+134.0%	+22.4%
Q2 24	+421.2%	+19.7%
Q3 24	-55.3%	+38.7%
Q4 24	-10.6%	+17.1%
Q1 25	-65.2%	+11.4%
Q2 25	-97.9%	+18.2%
Q3 25	-91.8%	+18.0%
Q4 25	-96.5%	+0.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	—
Q2 22	$3M	—
Q3 22	$0	—
Q4 22	$3M	—
Q1 23	$3M	10.9%
Q2 23	$0	0.0%
Q3 23	$0	0.0%
Q4 23	$4M	9.2%
Q1 24	$4M	6.3%
Q2 24	$5M	4.9%
Q3 24	$5M	24.8%
Q4 24	$5M	12.6%
Q1 25	$5M	24.7%
Q2 25	$5M	258.9%
Q3 25	$0	0.0%
Q4 25	$4M	335.5%

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$16M	$6M
Q2 22	$16M	$7M
Q3 22	$19M	$7M
Q4 22	$16M	$10M
Q1 23	$23M	$8M
Q2 23	$26M	$8M
Q3 23	$22M	$8M
Q4 23	$28M	$9M
Q1 24	$29M	$9M
Q2 24	$32M	$9M
Q3 24	$31M	$10M
Q4 24	$33M	$10M
Q1 25	$32M	$10M
Q2 25	$38M	$11M
Q3 25	$38M	$10M
Q4 25	$34M	$10M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$85M	$179M	$264M
Q2 22	$91M	$153M	$244M
Q3 22	$53M	$162M	$216M
Q4 22	$45M	$144M	$189M
Q1 23	$228M	$184M	$412M
Q2 23	$80M	$297M	$377M
Q3 23	$52M	$302M	$354M
Q4 23	$68M	$284M	$352M
Q1 24	$68M	$259M	$327M
Q2 24	$185M	$284M	$470M
Q3 24	$78M	$371M	$449M
Q4 24	$101M	$319M	$420M
Q1 25	$68M	$315M	$383M
Q2 25	$72M	$282M	$354M
Q3 25	$93M	$234M	$327M
Q4 25	$90M	$205M	$296M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	31M	+50.4%	+52.6%
Q2 22	31M	+0.1%	+52.7%
Q3 22	31M	+0.1%	+10.5%
Q4 22	31M	+0.2%	+50.9%
Q1 23	32M	+3.3%	+3.6%
Q2 23	33M	+2.4%	+6.0%
Q3 23	35M	+4.9%	+11.1%
Q4 23	33M	-4.0%	+6.4%
Q1 24	35M	+4.3%	+7.5%
Q2 24	36M	+2.1%	+7.1%
Q3 24	41M	+14.4%	+16.8%
Q4 24	43M	+6.0%	+29.0%
Q1 25	41M	-4.6%	+18.1%
Q2 25	41M	+0.6%	+16.4%
Q3 25	41M	+0.3%	+2.0%
Q4 25	41M	-0.2%	-3.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	114
Q2 22	$0	114
Q3 22	$0	114
Q4 22	$0	130
Q1 23	$194.3K	130
Q2 23	$139.8K	130
Q3 23	$336.4K	130
Q4 23	$263.2K	159
Q1 24	$371.8K	159
Q2 24	$595.6K	159
Q3 24	$123.1K	159
Q4 24	$204.4K	183
Q1 25	$112.3K	183
Q2 25	$10.7K	183
Q3 25	$8.8K	183
Q4 25	$87	15K

Revenue / Employee